2026 Peter N. Monk: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	53	16167	14845	1276	1179	158	10114

Overview

Peter N. Monk is affiliated with the University of Sheffield in the United Kingdom. Their research focuses primarily on medicine, with significant contributions also in biochemistry, genetics, and molecular biology.

The scientist's main fields of study include:

Medicine
Biochemistry, Genetics and Molecular Biology

Within these areas, their subfields of study cover:

Molecular Biology
Infectious Diseases
Ophthalmology
Molecular Medicine
Epidemiology

Peter N. Monk's research topics revolve around:

Ocular Infections and Treatments
Antibiotic Resistance in Bacteria
Bacterial biofilms and quorum sensing
Antimicrobial Resistance in Staphylococcus
Bacteriophages and microbial interactions
Complement system in diseases
Antimicrobial Peptides and Activities

Their recent publications include:

"The Influence of Biofilms on Carbapenem Susceptibility and Patient Outcome in Device Associated K. pneumoniae Infections: Insights Into Phenotype vs Genome-Wide Analysis and Correlation," 2020, Frontiers in Microbiology
"ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin," 2021, Cells
"Corneal Infection Models: Tools to Investigate the Role of Biofilms in Bacterial Keratitis," 2020, Cells
"Characterization of Ocular Clinical Isolates of Pseudomonas aeruginosa from Non-Contact Lens Related Keratitis Patients from South India," 2020, Microorganisms
"Hydrophobicity-Modulated Small Antibacterial Molecule Eradicates Biofilm with Potent Efficacy against Skin Infections," 2020, ACS Infectious Diseases

Frequent publication venues for Peter N. Monk include:

bioRxiv (Cold Spring Harbor Laboratory)
IUPHAR/BPS Guide to Pharmacology CITE
Cells
ACS Infectious Diseases
Scientific Reports

Collaborations have been established with several researchers notably including:

Lynda J. Partridge
Dhammika Leshan Wannigama
Esther Karunakaran
Anthony Kicic
Tanittha Chatsuwan

Best Publications

Characterization of Hepatitis C Virus E2 Glycoprotein Interaction with a Putative Cellular Receptor, CD81

Mike Flint;Catherine Maidens;Larry D. Loomis-Price;Christine Shotton

625
Citations
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells

Giuseppina Arbore;Erin E. West;Rosanne Spolski;Avril A. B. Robertson

532
Citations
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.

Jie Zhang;Glenn Randall;Adrian Higginbottom;Peter Monk

499
Citations
Function, structure and therapeutic potential of complement C5a receptors

Monk Pn;Scola Am;Madala P;Fairlie Dp

470
Citations
Cxc chemokine receptor expression on human endothelial cells.

Craig Murdoch;Peter N Monk;Adam Finn

349
Citations
Identification of Amino Acid Residues in CD81 Critical for Interaction with Hepatitis C Virus Envelope Glycoprotein E2

Adrian Higginbottom;Elizabeth R. Quinn;Chiung-Chi Kuo;Mike Flint

317
Citations
The Orphan Receptor C5L2 Has High Affinity Binding Sites for Complement Fragments C5a and C5a des-Arg74

Stuart A. Cain;Peter N. Monk

316
Citations
International Union of Basic and Clinical Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors

Andreas Klos;Elisabeth Wende;Kathryn J. Wareham;Peter N. Monk

314
Citations
Endothelial adhesion receptors are recruited to adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms

Olga Barreiro;Moreno Zamai;María Yáñez-Mó;Emilio Tejera

289
Citations
Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis.

Siranush A. Sargsyan;Peter N. Monk;Pamela J. Shaw

263
Citations
Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation.

Olga Barreiro;Olga Barreiro;Olga Barreiro;María Yáñez-Mó;María Yáñez-Mó;María Yáñez-Mó;Mónica Sala-Valdés;Mónica Sala-Valdés;Mónica Sala-Valdés;María Dolores Gutiérrez-López;María Dolores Gutiérrez-López;María Dolores Gutiérrez-López

258
Citations
The Chemoattractant Receptor-like Protein C5L2 Binds the C3a des-Arg77/Acylation-stimulating Protein

David Kalant;Stuart A. Cain;Magdalena Maslowska;Allan D Sniderman

240
Citations
C5L2 is a functional receptor for acylation stimulating protein

David Kalant;David Kalant;Robin MacLaren;Wei Cui;Ratna Samanta

233
Citations
Complement component 5a (C5a).

Helga D. Manthey;Trent M. Woodruff;Stephen M. Taylor;Peter N. Monk

222
Citations
Astrocyte function and role in motor neuron disease: a future therapeutic target?

Daniel Blackburn;Siranush Sargsyan;Peter N. Monk;Pamela J. Shaw

219
Citations
STRO-1, HOP-26 (CD63), CD49a and SB-10 (CD166) as markers of primitive human marrow stromal cells and their more differentiated progeny: a comparative investigation in vitro

Karina Stewart;Peter Monk;Susan Walsh;Carolyn M. Jefferiss

186
Citations
The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis

Trent M. Woodruff;Kerina J. Costantini;James W. Crane;Julie D. Atkin

180
Citations
The human complement fragment receptor, C5L2, is a recycling decoy receptor.

Anne-Marie Scola;Kay-Ole Johswich;B. Paul Morgan;Andreas Klos

176
Citations
Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration

Trent M. Woodruff;James W. Crane;Lavinia. M. Proctor;Kathryn M. Buller

173
Citations
Interleukin 3 stimulates proliferation via protein kinase C activation without increasing inositol lipid turnover.

A D Whetton;P N Monk;S D Consalvey;S J Huang

138
Citations